Abstract
One thing we know for certain after decades of functional imaging in schizophrenia is that it is not a disorder that can simply be attributed to circumscribed lesions in the brain. It is, in other words, a disorder of the connectivity of the brain. In this overview, we will consider the power of connectivity analyses of functional MRI (and PET) data as tools for translational neuroscience. We describe the patterns of functional and effective disconnectivity seen in schizophrenia and particular psychotic symptoms, those that appear to be attributable to genetic and/or environmental risk factors for psychosis, the potential of these disconnectivities as trait and state biomarkers, and their sensitivity to drug effects. We conclude that substantial work needs to be done on standardising connectivity analyses across laboratories and that disconnectivity studies should be an integral part of drug discovery programmes.
Keywords: Connectivity, fMRI, schizophrenia
Current Pharmaceutical Design
Title: Connecting the Brain and New Drug Targets for Schizophrenia
Volume: 15 Issue: 22
Author(s): H. C. Whalley, J. D. Steele, P. Mukherjee, L. Romaniuk, A. M. McIntosh, J. Hall and S. M. Lawrie
Affiliation:
Keywords: Connectivity, fMRI, schizophrenia
Abstract: One thing we know for certain after decades of functional imaging in schizophrenia is that it is not a disorder that can simply be attributed to circumscribed lesions in the brain. It is, in other words, a disorder of the connectivity of the brain. In this overview, we will consider the power of connectivity analyses of functional MRI (and PET) data as tools for translational neuroscience. We describe the patterns of functional and effective disconnectivity seen in schizophrenia and particular psychotic symptoms, those that appear to be attributable to genetic and/or environmental risk factors for psychosis, the potential of these disconnectivities as trait and state biomarkers, and their sensitivity to drug effects. We conclude that substantial work needs to be done on standardising connectivity analyses across laboratories and that disconnectivity studies should be an integral part of drug discovery programmes.
Export Options
About this article
Cite this article as:
Whalley C. H., Steele D. J., Mukherjee P., Romaniuk L., McIntosh M. A., Hall J. and Lawrie M. S., Connecting the Brain and New Drug Targets for Schizophrenia, Current Pharmaceutical Design 2009; 15 (22) . https://dx.doi.org/10.2174/138161209788957500
DOI https://dx.doi.org/10.2174/138161209788957500 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Pathogenic Role of Persistent Milk Signaling in mTORC1- and Milk- MicroRNA-Driven Type 2 Diabetes Mellitus
Current Diabetes Reviews Protective Effects of Corticosteroids and Neurosteroids on Cochlear injury
Medicinal Chemistry Impulse Control Disorders in Parkinson’s Disease: A Review
Current Psychiatry Reviews Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease
Current Pharmaceutical Design Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry Disrupted Structural Brain Network in AD and aMCI: A Finding of Long Fiber Degeneration
Current Alzheimer Research Familial Non-Syndromic Clear Cell Renal Cell Carcinoma
Current Molecular Medicine Inflammation-Associated Changes in Bone Homeostasis
Inflammation & Allergy - Drug Targets (Discontinued) Resistin and Oxidative Stress in Non-Diabetic Obstructive Sleep Apnea Patients with Nocturnal Hypertension
Current Respiratory Medicine Reviews The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Old and New Antiepileptic Drugs for the Treatment of Idiopathic Generalized Epilepsies
Current Clinical Pharmacology Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research Intestinal Barrier Dysfunction in Human Pathology and Aging
Current Pharmaceutical Design 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology Haemodynamic Regulation of Gene Expression in Vascular Tissue Engineering
Current Vascular Pharmacology CREB, Synapses and Memory Disorders: Past Progress and Future Challenges
Current Drug Targets - CNS & Neurological Disorders The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews New Chemotherapeutic Strategies Against Malaria, Leishmaniasis and Trypanosomiases
Current Medicinal Chemistry